Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | +6.61% | +13.62% | +89.06% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 158M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M | Net cash position 2025 * | 50.8M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-3.97
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | +6.61% | ||
1 week | +13.62% | ||
Current month | -15.97% | ||
1 month | -14.94% | ||
3 months | +92.06% | ||
6 months | +90.55% | ||
Current year | +89.06% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.42 | +6.61% | 204,765 |
24-04-25 | 2.27 | +2.25% | 97,798 |
24-04-24 | 2.22 | -1.77% | 91,807 |
24-04-23 | 2.26 | +2.73% | 101,587 |
24-04-22 | 2.2 | +3.29% | 127,753 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.06% | 158M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RGLS Stock